---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-297165"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:02:32.219283+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve 2025 equity plan and executive option repricing to $1.50

## Summary
- 2025 Stock Incentive Plan approved with 30.5M for, 2.9M against.
- CEO René Russo's 2,198,212 options repriced from $5.76 to $1.50.
- CFO Christopher Frankenfield's 848,172 options repriced from $4.67 to $1.50.
- CMO Katarina Luptakova's 225,210 options repriced from $4.10 to $1.50; effective after market close Nov 21.

## SEC filing metadata
- accession: 0001193125-25-297165
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/0001193125-25-297165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312525297165/xlo-20251121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-297165
- JSON: https://secwatch.observer/filing/0001193125-25-297165.json
- Plain text: https://secwatch.observer/filing/0001193125-25-297165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.